CN101379066B - Hcv ns5b抑制剂 - Google Patents

Hcv ns5b抑制剂 Download PDF

Info

Publication number
CN101379066B
CN101379066B CN2007800049834A CN200780004983A CN101379066B CN 101379066 B CN101379066 B CN 101379066B CN 2007800049834 A CN2007800049834 A CN 2007800049834A CN 200780004983 A CN200780004983 A CN 200780004983A CN 101379066 B CN101379066 B CN 101379066B
Authority
CN
China
Prior art keywords
cyclohexyl
indolo
methyl
benzazepine
formic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800049834A
Other languages
English (en)
Chinese (zh)
Other versions
CN101379066A (zh
Inventor
C·P·伯格斯特伦
S·W·马丁
T·W·休迪马
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN101379066A publication Critical patent/CN101379066A/zh
Application granted granted Critical
Publication of CN101379066B publication Critical patent/CN101379066B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
CN2007800049834A 2006-02-08 2007-02-07 Hcv ns5b抑制剂 Expired - Fee Related CN101379066B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US77139106P 2006-02-08 2006-02-08
US60/771,391 2006-02-08
PCT/US2007/061768 WO2007092888A2 (en) 2006-02-08 2007-02-07 Hcv ns5b inhibitors

Publications (2)

Publication Number Publication Date
CN101379066A CN101379066A (zh) 2009-03-04
CN101379066B true CN101379066B (zh) 2011-08-03

Family

ID=38234480

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800049834A Expired - Fee Related CN101379066B (zh) 2006-02-08 2007-02-07 Hcv ns5b抑制剂

Country Status (17)

Country Link
US (1) US7456165B2 (enExample)
EP (1) EP1987038B1 (enExample)
JP (1) JP5147731B2 (enExample)
KR (1) KR20080102161A (enExample)
CN (1) CN101379066B (enExample)
AT (1) ATE483712T1 (enExample)
AU (1) AU2007211988B2 (enExample)
CY (1) CY1111423T1 (enExample)
DE (1) DE602007009646D1 (enExample)
DK (1) DK1987038T3 (enExample)
ES (1) ES2352574T3 (enExample)
HR (1) HRP20100672T1 (enExample)
NO (1) NO20083513L (enExample)
PL (1) PL1987038T3 (enExample)
PT (1) PT1987038E (enExample)
SI (1) SI1987038T1 (enExample)
WO (1) WO2007092888A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005049622A1 (ja) * 2003-11-19 2007-06-07 日本たばこ産業株式会社 ５−５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
ATE469155T1 (de) * 2006-05-25 2010-06-15 Bristol Myers Squibb Co Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b- hemmer
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) * 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541352B2 (en) * 2007-02-02 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) * 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
BRPI0821342A2 (pt) 2007-12-19 2019-09-24 Boehringer Ingelheim Int inibidores da polimerase viral
WO2009120733A1 (en) * 2008-03-27 2009-10-01 Bristol-Myers Squibb Company Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors
JP2011515496A (ja) * 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー ジオキソランおよびジオキソラノン縮合インドロベンザジアゼピンｈｃｖｎｓ５ｂ阻害剤
CN101977914A (zh) * 2008-03-27 2011-02-16 百时美施贵宝公司 用于治疗丙型肝炎的化合物
KR20100124848A (ko) 2008-03-27 2010-11-29 브리스톨-마이어스 스큅 컴퍼니 방향족 헤테로시클릭 융합된 인돌로벤자디아제핀 ｈｃｖ ｎｓ5ｂ 억제제
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
CN102271699A (zh) 2009-01-07 2011-12-07 西尼克斯公司 用于治疗hcv和hiv感染的环孢菌素衍生物
JP2012517468A (ja) * 2009-02-11 2012-08-02 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎治療のための化合物
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
CA2822357A1 (en) 2010-12-22 2012-06-28 Abbvie Inc. Hepatitis c inhibitors and uses thereof
JP2014502620A (ja) 2010-12-30 2014-02-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状ｃ型肝炎セリンプロテアーゼ阻害剤
WO2012092411A2 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc. Phenanthridine macrocyclic hepatitis c serine protease inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
CN102276531A (zh) * 2011-05-30 2011-12-14 扬子江药业集团广州海瑞药业有限公司 一种甲磺酸非诺多泮的制备方法
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
CN104447952A (zh) * 2014-12-11 2015-03-25 上海唐润医药科技有限公司 丙肝病毒蛋白酶抑制剂及其合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004092162A1 (en) * 2003-04-11 2004-10-28 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US20050119318A1 (en) * 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication
CN1684683A (zh) * 2002-09-30 2005-10-19 贝林格尔英格海姆国际有限公司 Hcv丝氨酸蛋白酶的有效抑制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1719773B1 (en) 2004-02-24 2009-04-15 Japan Tobacco, Inc. Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
ES2300054T3 (es) 2004-10-13 2008-06-01 Merck Patent Gmbh Derivados de la n,n'- difenilurea adecuados como inhibidores de cinasas.
AU2005298412B2 (en) 2004-10-26 2011-06-09 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1684683A (zh) * 2002-09-30 2005-10-19 贝林格尔英格海姆国际有限公司 Hcv丝氨酸蛋白酶的有效抑制剂
WO2004092162A1 (en) * 2003-04-11 2004-10-28 Vertex Pharmaceuticals, Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US20050119318A1 (en) * 2003-10-31 2005-06-02 Hudyma Thomas W. Inhibitors of HCV replication

Also Published As

Publication number Publication date
PL1987038T3 (pl) 2011-03-31
SI1987038T1 (sl) 2011-02-28
ATE483712T1 (de) 2010-10-15
CN101379066A (zh) 2009-03-04
JP5147731B2 (ja) 2013-02-20
HRP20100672T1 (hr) 2011-01-31
KR20080102161A (ko) 2008-11-24
AU2007211988B2 (en) 2012-02-02
WO2007092888A3 (en) 2007-10-11
NO20083513L (no) 2008-10-14
WO2007092888A2 (en) 2007-08-16
DK1987038T3 (da) 2011-01-31
US20070185083A1 (en) 2007-08-09
CY1111423T1 (el) 2015-08-05
DE602007009646D1 (de) 2010-11-18
EP1987038A2 (en) 2008-11-05
AU2007211988A1 (en) 2007-08-16
EP1987038B1 (en) 2010-10-06
JP2009526081A (ja) 2009-07-16
PT1987038E (pt) 2010-12-09
US7456165B2 (en) 2008-11-25
ES2352574T3 (es) 2011-02-21

Similar Documents

Publication Publication Date Title
CN101379066B (zh) Hcv ns5b抑制剂
CN101657455B (zh) 用于治疗丙型肝炎的化合物
US7485633B2 (en) Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN101679441B (zh) 用于治疗丙型肝炎的化合物
EP3042901B1 (en) Hepatitis c virus inhibitors
CN101918406B (zh) 用于治疗丙型肝炎的化合物
US7473688B2 (en) Indolobenzazepine HCV NS5B inhibitors
CN101730698B (zh) 用于治疗丙型肝炎的化合物
CN101754966B (zh) 丙型肝炎病毒抑制剂
JP2022071046A (ja) Ｗｄｒ５タンパク質－タンパク質結合の阻害剤
EP2024375B1 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
CN101918410B (zh) 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
CN101679442B (zh) 用于治疗丙型肝炎的化合物
CN101821267B (zh) 用于治疗丙型肝炎的化合物
TW200938192A (en) Hepatitis C virus inhibitors
CN101541784A (zh) 丙型肝炎病毒抑制剂
CN101918412B (zh) 用于治疗丙型肝炎的稠合有环丙基的吲哚并苯并氮杂*衍生物
EP2121694B1 (en) Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
CN102083834A (zh) 用于治疗丙型肝炎的7H-吲哚并[2，1-a][2]苯并氮杂*-10-羧酸衍生物
CN101443336B (zh) 环丙基稠合的[吲哚]并[苯并氮杂*]hcv ns5b抑制剂
JP2016527232A (ja) Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ
CN101952289A (zh) 用于治疗黄病毒感染的稠合五环衍生物
HK1254511A1 (en) Compounds for preparing hepatitis c virus inhibitors
HK1226737B (en) Hepatitis c virus inhibitors
HK1226737A1 (en) Hepatitis c virus inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110803

Termination date: 20150207

EXPY Termination of patent right or utility model